Atossa Therapeutics (NASDAQ:ATOS) Announces Earnings Results

Atossa Therapeutics (NASDAQ:ATOS) announced its quarterly earnings results on Monday. The company reported ($0.06) EPS for the quarter, Yahoo Finance reports.

Atossa Therapeutics Price Performance

NASDAQ ATOS opened at $1.84 on Wednesday. The firm has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $0.90. Atossa Therapeutics has a 12-month low of $0.59 and a 12-month high of $2.11.

Wall Street Analyst Weigh In

ATOS has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Atossa Therapeutics in a report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 18th.

Institutional Trading of Atossa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ATOS. Millennium Management LLC bought a new stake in shares of Atossa Therapeutics during the 2nd quarter worth approximately $1,673,000. Renaissance Technologies LLC lifted its holdings in shares of Atossa Therapeutics by 79.5% during the 1st quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company’s stock worth $2,626,000 after acquiring an additional 930,152 shares during the period. Bank of Montreal Can bought a new stake in shares of Atossa Therapeutics during the 2nd quarter worth approximately $365,000. GSA Capital Partners LLP lifted its holdings in shares of Atossa Therapeutics by 29.3% during the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock worth $395,000 after acquiring an additional 101,690 shares during the period. Finally, State Street Corp lifted its holdings in shares of Atossa Therapeutics by 4.2% during the 1st quarter. State Street Corp now owns 2,233,010 shares of the company’s stock worth $2,791,000 after acquiring an additional 90,960 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.